These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35597061)

  • 1. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
    Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
    J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of 28 cases of anti
    Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
    Bastiaansen AEM; van Sonderen A; Titulaer MJ
    Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
    Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
    J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides.
    Seery N; Butzkueven H; O'Brien TJ; Monif M
    Autoimmun Rev; 2022 May; 21(5):103074. PubMed ID: 35247644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
    Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
    Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.
    Vincent A; Pettingill P; Pettingill R; Lang B; Birch R; Waters P; Irani SR; Buckley C; Watanabe O; Arimura K; Kiernan MC
    JAMA Neurol; 2018 Dec; 75(12):1519-1527. PubMed ID: 30242309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-VGKC Complex Antibodies and Limbic Encephalitis].
    Tanaka K
    Brain Nerve; 2021 May; 73(5):605-610. PubMed ID: 34006694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.
    Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K
    Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
    Michael S; Waters P; Irani SR
    Pract Neurol; 2020 Oct; 20(5):377-384. PubMed ID: 32595134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
    Huang X; Fan C; Gao L; Li L; Ye J; Shen H
    J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis.
    Gövert F; Abrante L; Becktepe J; Balint B; Ganos C; Hofstadt-van Oy U; Krogias C; Varley J; Irani SR; Paneva S; Titulaer MJ; de Vries JM; Boon AJW; Schreurs MWJ; Joubert B; Honnorat J; Vogrig A; Ariño H; Sabater L; Dalmau J; Scotton S; Jacob S; Melzer N; Bien CG; Geis C; Lewerenz J; Prüss H; Wandinger KP; Deuschl G; Leypoldt F
    Brain; 2023 Feb; 146(2):657-667. PubMed ID: 35875984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
    Klein CJ; Lennon VA; Aston PA; McKeon A; O'Toole O; Quek A; Pittock SJ
    JAMA Neurol; 2013 Feb; 70(2):229-34. PubMed ID: 23407760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex.
    Montojo MT; Petit-Pedrol M; Graus F; Dalmau J
    Neurologia; 2015 Jun; 30(5):295-301. PubMed ID: 24485651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.
    Lang B; Makuch M; Moloney T; Dettmann I; Mindorf S; Probst C; Stoecker W; Buckley C; Newton CR; Leite MI; Maddison P; Komorowski L; Adcock J; Vincent A; Waters P; Irani SR
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):353-361. PubMed ID: 28115470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep Disorders in Leucine-Rich Glioma-Inactivated Protein 1 and Contactin Protein-Like 2 Antibody-Associated Diseases.
    Lin N; Hao H; Guan H; Sun H; Liu Q; Lu Q; Jin L; Ren H; Huang Y
    Front Neurol; 2020; 11():696. PubMed ID: 32849186
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
    Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
    Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-voltage-gated potassium channel (VGKC) complex/leucine-rich glioma-inactivated protein 1 (LGI1) antibody-associated limbic encephalitis mimicking dementia with Lewy bodies in a patient with subacute REM sleep behavior disorder].
    Arakawa I; Oguri T; Nakamura T; Sakurai K; Yuasa H
    Rinsho Shinkeigaku; 2022 Jan; 62(1):22-26. PubMed ID: 34924467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
    Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
    Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis.
    Baumgartner T; Pitsch J; Olaciregui-Dague K; Hoppe C; Racz A; Rüber T; Becker A; von Wrede R; Surges R
    Epilepsia; 2022 Sep; 63(9):e100-e105. PubMed ID: 35735209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.